Member Info for Scharnhorst

They have no scientific advantage. The genetic code for the spike protein has been open source for months. The differentiation with the Oxford vaccine is the adenoviral vector which has nothing to do with ODX who are just manufacturers of plastic test kits in any case.

Abingdon think they will still get approval for self-test use at home. Dream on.

Thanks. They didn't give much away but all positive about Mercia, especially at the end. I'm expecting an update on the veros covid test soon.

The RTC lateral flow antibody test isn't the gold standard. Why would you want them to put out a lie? We've had enough of those.

The Board has signalled valuation uplifts. Oxgene goes from strength to strength and the investment in Sense Bio was better late than never. Sentiment might improve if, like the Royal Oak, Herr Biden can pour oil on troubled waters.
The Zeiss and my tired eyes get a well-earned rest during the winter. My intelligence wing tells me an institution continues to sell down, holding the price back. I hope the schnapps isn't dulling their reports.

Release date Tuesday 1st December
VIP preview 9.30am
Matinee 3pm

To reduce ballast, whoever keeps throwing money at ill-conceived Concepta could perhaps be sent on a one-way cruise on the Grand Union Canal.

Instead of making a convincing case for adding another director they make board meetings sound like a debating society.

I hope the fish make up for the difficulties you are facing thanks to your service dominated economy and determination to leave your European friends. At least Sense Bio will make a positive contribution to your trade deficit. Meanwhile we go on earning Marks.

You say scuppered, vee say sh@ on your sea bed.

Ja, a very exciting company. Let us hope zey vill do to Lateral Flow vot ve did to Scapa Flow.

It’s the way you tell ‘em...I hoped for better after a week of deliberation.

Ja, I vill vork on my delivery. Were you a scriptwriter for ‘Allo ‘Allo! perchance?

Yes ve intercepted ze message about ze EIS, but ve are Von Mercia now, no? Ze 25x uplift example better read across vell to ze direct portfolio else ve vill be adding some Henley in Arden names to ze list, Gott im Himmel! Heil Hitler!

Just 3-months after selling Native Antigen Company for 8.6x cost, from which Mercia won Best EIS Exit 2020 at the EISA 2020 Awards announced last week, the EIS has exited the EIS portfolio company Clear Review for 8.0x cost, and an impressive 122% IRR.
Obersignalmeister Gustave Lorentz reports news flow over the horizon.
“This exit is indicative of the maturation of the Mercia EIS portfolio. The company reports that it is working on at least another five realisations, at multiples of between 1.5x and 25x cost. Further details will be announced in due course.”

The article states the lamp test by Collinson is better than the antigen tests (Mologic).

I can't recall them mentioning this one. It must have been one of the 'others' in the annual report portfolio list.

http://www.mercia.co.uk/wp-content/uploads/Mercia_Technologies_PLC_-_Capital_Markets_Day_2018_fMEft1m.pdf
This is two years old but gives some background information on Oxgene. I wish I had the intelligence of Ryan Cawood.

https://www.mercia.co.uk/webinar-the-native-antigen-company-exit-for-mercia-eis-fund/
I found the above webinar informative. It covers the Native Antigen Company sale but there is a wider discussion about life sciences. I didn't realize NAC had been part of another portfolio company, PsiOxus. An 8x return for MERC investors on a spin out company looks pretty good to me.

I think your timing is good. On fundamentals we have good asset backing (share price c30% discount to NAV not including third party funds under management), good exposure to healthcare which is obviously in a growth phase and some promising tech and software companies. My favourite portfolio company is Oxgene, one of the UKs fastest growing small companies. Abingdon health is also in a good space though not yet in the direct portfolio.
On the charts we’re flirting just above the 200 day ma. That hasn’t happened often since IPO and if we can keep the current momentum going we could wave goodbye to the long term downtrend. Good luck.
ps I’m not a fan of paid research but Edison have just released an update and a directors’ interview which give some background on their life sciences investments.